Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
I’m no Chartist, but I’d say that the gap has been closed.
AVCT opened with a 10p gap up to 98p then quickly traded up to 105p followed by a couple hundred or so trades back down to 89p to match last nights close, before resuming its path to tonight’s close at 99.6p.
I don’t get why so many holders are willing to sell at this price level? the shorters are getting off very lightly in my opinion.
Like many holders here, I’ve been busy reducing my average substantially during the past couple of months, for the long term.
Thanks!
I noticed that Alastair was very keen to make the point that Avacta will be taking it forward themselves. I also took his relative calm delivery, lacking the superlatives of past presentations, to be sign of quiet confidence.
Bella, on previous days, big numbers after the bell have been labelled as balancing trades by some posters. What makes you suggest this is different than usual?
Thinking aloud; maybe the clue is that the price is a very specific 0.89863 pence over the closing price, which could potentially be arrived at by calculating the average price for a load of trades completed for one order? Jupiter?
The FDA link refers to a test from Tide Labatories LLC that failed to detect Omicron adequately. I may be wrong but my interpretation is that the issue was resolved, resulting in a 100% match for Omicron, in just five days, over Christmas.
Trinity Delta view:
This clearly disappointing news effectively pushes back the commercialisation of the AffiDX SARS-CoV-2 LFT. The positives are that management has identified the issue and responded promptly and, importantly, the issue does not lie with the Affimer technology. Avacta’s Diagnostics business demonstrated its technical abilities and the ability to react rapidly to problems when creating the original LFT, hence it will hopefully resolve this issue quickly too. We note that there is also the possibility that the sensitivity of other marketed COVID-19 LFTs to Omicron may be similarly impacted. The uncertainties around timelines, in addition to the challenging market environment, prompt us to suspend our forecasts and valuation until there is greater visibility. Our prior Avacta valuation was £710m (280p per share), with the Diagnostic opportunities representing £133m.
We continue to view the Therapeutics pipeline as the greater driver of long-term value; our £559m rNPV for the Affimer and pre|CISION platforms is unaffected by this announcement.
East side, you’re totally right!
I’ve been giving Medusa the benefit of doubt purely because everybody else does, all seems to be based on wishful thinking, a wing and prayer. Medusa do seem to have attracted the ‘marketing experts’ mantra, but in the visible world there’s simply nothing to back it up, no evidence of any marketing or other activity. The website is an embarrassment, the least they could do is remove the picture and bio of their managing director who resigned six months ago.
But even with the poor visibility and lack of marketing evidence, I hang on to my sizeable share holding with a tight grip, in the firm belief that we’ll all be surprised to the upside soon enough. I thought the MeduFlow brochure saga was a scam until confirmed in the HUA RNS.
Everything we’ve heard about Medusa19, their world renowned business team, AVCT holdings etc, just isn’t compatible with their amateur, out of date website. News blackout for nearly a year, even the photo and bio for their managing director is for someone who resigned from the board back in July 21. I find the poor and mixed up image presented by the website quite bothersome and not reflective of a world class team, but I somehow overlook it and go with the flow with everyone else.
Remember brochuregate? An picture of a badly compiled leaflet, with cut & paste images from an antibody diagram and with spelling mistakes, the only one in existence somehow getting left behind, photographed, placed on Twitter and shrouded in mystery. Surely MeduFlow had to be a big wind up, let alone all the Medusa related rumours flying around after JayKays 1hr 46minute telephone call! But confirmation soon came in the form of an RNS, not only confirming MeduFlow, but MeduFlow with UK/EU HUA! A shock for some, and even‘The Bishop’ deleted his account.
So, what are we to think of the possibility of Meduflow/AffiDX being granted EUA by the FDA?
I also sent message to Shadow H Sec, also pointing out his missed opportunity to castigate the Tory front bench when Neale Hanvey put them on the spot. I did get a response, to say that he receives thousands of emails. :( nothing about the topic!
Other MP’s have just give me stock answers to my lobbying for UK diagnostics, the content of which reveal their collective ignorance, in spades!
There may well be no particular reason for the delay, other than the sheer volume of documents that need to be aligned at the final moment for signing, and then for translating what’s needed to form the admissions document.
The logistics of it all will be way beyond the imagination of most observers. A simple Share Purchase Agreement is complex enough and time consuming, and I think it’s a huge credit to AK and team to get SAVE to this place in just six months!
It’s a mammoth task to get all this stuff in order, to the extent where all parties and their lawyers can agree. I don’t envy them the task and I’m very happy to wait.
Merry Christmas from a happy shareholder! :)
Thanks Bella, completely missed in the excitement!
I received 25 AffiDX yesterday. Great, although the multilingual instruction sheet is the size of an ordinance survey map, and you need a magnifying glass to read them! Hopefully just the professional version.